Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Here’s What Happened

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $16.36, but opened at $15.57. Daiichi Sankyo shares last traded at $15.36, with a volume of 5,755 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy”.

Daiichi Sankyo Stock Performance

The stock has a market cap of $28.60 billion, a P/E ratio of 16.06, a price-to-earnings-growth ratio of 1.08 and a beta of -0.16. The firm’s 50-day moving average is $17.17 and its two-hundred day moving average is $19.39. The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.18). The business had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.74%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, research analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.91 EPS for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.